Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy

被引:50
|
作者
Lian, Shu [1 ]
Xie, Xiaodong [1 ]
Lu, Yusheng [1 ,2 ]
Jia, Lee [1 ,2 ]
机构
[1] Fuzhou Univ, Coll Chem, Canc Metastasis Alert & Prevent Ctr, Fuzhou, Fujian, Peoples R China
[2] Minjiang Univ, Inst Oceanog, Marine Drug R&D Ctr, Xiyuangong Rd, Fuzhou 350108, Fujian, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2019年 / 12卷
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
CD47; immune therapy; biological target; immune checkpoint; INTEGRIN-ASSOCIATED PROTEIN; SIRP-ALPHA; T-CELL; TARGETING CD47; POOR-PROGNOSIS; STEM-CELLS; CANCER; MIGRATION; BLOCKADE; PHAGOCYTOSIS;
D O I
10.2147/OTT.S220196
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The success of cancer immunotherapy on recognition checkpoints for killing cancer cells has raised a great interest of scientists in understanding new and old methods of immunotherapeutic. CD47 (cluster of differentiation 47) is a cell surface glycoprotein and widely expressed on cells, which belongs to the immunoglobulin (Ig) superfamily as a cell membrane receptor which serves in immune therapy. CD47 is an inhibitory receptor expressed on tumor cell surface and interacts with signal receptor protein-alpha (SIPR-alpha, also named CD172 alpha or SHPS-1) which may escape from immune cells such as macrophage and T cells. Meanwhile, tumor cells express high CD47 protein which may secrete exosomes with high CD47 expression. The high CD47 expression-exosomes could serve the tumor metastasis process and provide transfer convenience for tumors on the microenvironment. CD47 on cancer cells can also affect the migration and invasion of cells. The high CD47 expression on tumor or CTC (circulating tumor cell) surface means the stronger migration and invasion and makes them escape from immune cells for phagocytosis such as T cells, NK (natural killer) cells and macrophage, which could be used for diagnosis and prognosis on cancer patients. Meanwhile, targeting CD47 combined with other biomarkers such as EpCAM (epithelial cell adhesion molecule), CD44, etc on cancer surface could be used to isolate CTCs from patients' blood. In terms of treatment, anti-CD47 antibody combined with another antibody such as anti-PD-L1 (programmed death-ligand 1) antibody or drugs such as rituximab, DOX or oxaliplatin also has better therapeutic effects and antitumor function to tumors. Using nanomaterials as an intermediary for CD47-related immune therapy could greatly increase the therapeutic effect and overcome multiple biological barriers for anti-CD47 antibody in vivo. In this review, we discuss the important role and the function of CD47 in tumor metastasis and also provide a reference for related research.
引用
收藏
页码:9105 / 9114
页数:10
相关论文
共 50 条
  • [41] CD47 checkpoint data supercharge Stanford spinout IPO
    Dolgin, Elie
    [J]. NATURE BIOTECHNOLOGY, 2018, 36 (08) : 671 - 672
  • [42] RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation
    Lian Zhang
    Jing Yu
    Mingyue Zheng
    Hui Zhen
    Qingqiang Xie
    Chundong Zhang
    Zhongjun Zhou
    Guoxiang Jin
    [J]. Communications Biology, 6
  • [43] RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation
    Zhang, Lian
    Yu, Jing
    Zheng, Mingyue
    Zhen, Hui
    Xie, Qingqiang
    Zhang, Chundong
    Zhou, Zhongjun
    Jin, Guoxiang
    [J]. COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [44] Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice
    Li, Yang
    Zhang, Mingyou
    Wang, Xiaodan
    Liu, Wentao
    Wang, Hui
    Yang, Yong-Guang
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [45] Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice
    Yang Li
    Mingyou Zhang
    Xiaodan Wang
    Wentao Liu
    Hui Wang
    Yong-Guang Yang
    [J]. Nature Communications, 11
  • [46] Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer
    Yu, Lan
    Ding, Yi
    Wan, Ting
    Deng, Ting
    Huang, He
    Liu, Jihong
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [47] Cancer Therapy Targeting CD47/SIRPα
    Dizman, Nazli
    Buchbinder, Elizabeth I.
    [J]. CANCERS, 2021, 13 (24)
  • [48] The anti-tumor effect of radiation therapy is enhanced with the addition of TTI-621 (SIRPaFc), an immune checkpoint inhibitor blocking the CD47 "do not eat" signal
    Cui, Lei
    Chen, Hui
    O'Connor, Alison
    Jin, Debbie
    Winston, Jeffrey
    Uger, Robert
    Johnson, Lisa
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [49] Cd47: A new target in cardiovascular therapy
    Isenberg, Jeff S.
    Roberts, David D.
    Frazier, William A.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (04) : 615 - 621
  • [50] CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
    Lau, Asa P. Y.
    Binstock, Sharon S. Khavkine
    Thu, Kelsie L.
    [J]. CANCERS, 2023, 15 (21)